Gastrointestinal Specialists of Georgia

Summary

Gastrointestinal Specialists of Georgia is a medical facility located in Marietta, Georgia. This center is recognized for care of Nonalcoholic Steatohepatitis, Hepatitis C, Non-alcoholic Fatty Liver Disease, Ulcerative Colitis, Crohn's Disease and other specialties. Gastrointestinal Specialists of Georgia is involved with conducting 77 clinical trials across 65 conditions. There are 2 research doctors associated with this hospital, such as Aasim Sheikh, MD and Aasim M. Sheikh.

Top PIs

Clinical Trials running at Gastrointestinal Specialists of Georgia

Fatty Liver Disease

Clostridium Difficile Infection

Diarrhea

Clostridium difficile infection

C. diff infection

Crohn's Disease

Fatty Liver

Nonalcoholic Steatohepatitis

Clostridioides difficile Infection

C. difficile Infection

Survodutide

for Fatty Liver Disease

This study is open to adults who are at least 18 years old and have: * A confirmed liver disease called non-alcoholic steatohepatitis (NASH) or * A confirmed liver disease called metabolic-associated steatohepatitis (MASH) * BMI of 27 kg/m2 or more or * 25 kg/m2 or more if the participant is Asian. People with a history of other chronic liver diseases or high alcohol intake cannot take part in this study. The purpose of this study is to find out whether a medicine called survodutide helps people with NASH or MASH improve their liver function. Participants are put into 2 groups randomly, which means by chance. 1 group gets survodutide and 1 group gets placebo. Placebo looks like survodutide but does not contain any medicine. Each participant has twice the chance of getting survodutide. Participants and doctors do not know who is in which group. Participants inject survodutide or placebo under their skin once a week. All participants regularly receive counselling to make changes to their diet and to exercise regularly. Participants are in the study for up to 4 and a half years. During this time, they visit the study site or have a remote visit by video call every 2, 4 or 6 weeks for about a 1 year and 5 months. After this time participants visit the trial site or have a remote visit every 3 months until the end of the study. The doctors check participants' health and take note of any unwanted effects. The participants' body weight is regularly measured. At some visits the liver parameters are measured using different imaging methods. The participants also fill in questionnaires about their symptoms. The results are compared between the groups to see whether the treatment works.

Recruiting

1 award

Phase 3

2 criteria

Tirzepatide + Retatrutide

for Fatty Liver Disease

The main purpose of the SYNERGY-OUTCOMES study is to find out whether retatrutide and tirzepatide can prevent major adverse liver outcomes (MALO) in people with high-risk metabolic dysfunction-associated steatotic liver disease (MASLD). The study will enroll adults who have MASLD based on non-invasive tests (NITs), which indicate they are more likely to develop MALO. Participants will be randomly assigned within a Master Protocol to receive either retatrutide (N1T-MC-RT01), tirzepatide (N1T-MC-TZ01) or placebo. The trial plans to enroll about 4,500 adults and will run for approximately 224 weeks. Participants may have up to approximately 25 to 30 clinic visits throughout the study to monitor their health, complete study procedures, and assess liver function and disease progression. Once the study is complete, eligible participants may participate in an optional 2-year extension study, in which all participants will receive either retatrutide or tirzepatide, even if they received placebo in the main study.

Recruiting

1 award

Phase 3

1 criteria

Efimosfermin

for Fatty Liver Disease

The purpose of this study is to evaluate the safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of efimosfermin in participants with metabolic dysfunction associated steatohepatitis (MASH) and compensated cirrhosis consistent with stage F4 fibrosis.

Recruiting

0 awards

Phase 2

3 criteria